Asteri Pharma Pty Ltd (Asteri Pharma) is pleased to announce the expansion of our strategic partnership with Esteve, becoming the exclusive licensing partner for two additional therapies within Esteve’s Endocrinology and Oncology portfolio. This expanded portfolio introduces innovative therapies that play a vital role in the management of rare endocrinology and neuroendocrinology conditions, including Cushing’s syndrome and other complex disorders. These additions seamlessly complement our...

Australian based biopharmaceutical company Asteri Pharma Pty Ltd (ASTERI Pharma) is proud to partner with ESTEVE, an international specialty pharmaceutical company headquartered in Spain, to provide continued access to a biologic product for children and adolescents aged 2 to 18 with severe primary insulin-like growth factor 1 deficiency (SPIGFD).   ASTERI Pharma’s partnership with ESTEVE highlights its focus on growth in rare disease treatment and meeting unmet patient needs.    ASTERI...

Australian based biopharmaceutical company ASTERI Pharma Pty Ltd, (ASTERI) is proud to partner with ITALFARMACO, a private multinational group headquartered in Milan, Italy, to continue to commercialise an oral suspension therapy to treat Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease (MND) 1  in Australia and New Zealand. Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease of motor neurons in the brain and spinal cord, resulting...